Litcius/Paper detail

Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome

Marit Jalink, Sigbjørn Berentsen, Jorge J. Castillo, Steven P. Treon, Marjan Cruijsen, Bruno Fattizzo, Ramona Cassin, Despina Fotiou, Efstathios Kastritis, Masja de Haas, Liesbeth E.M. Oosten, Henrik Frederiksen, Andrea Patriarca, Shirley D’Sa, Josephine M. I. Vos

2021Blood56 citationsDOIOpen Access PDF

Abstract

Cold antibody-mediated autoimmune hemolytic anemia (cAIHA) is a rare disease, usually related to an underlying indolent clonal B-cell lymphoproliferative disorder. Jalink and colleagues describe an international retrospective analysis of Bruton tyrosine kinase (BTK) inhibition in patients with cAIHA. The data indicate a rapid and notable improvement in both the hemolytic anemia as well as acrocyanosis, suggesting that this may be an effective approach, regardless of underlying pathology or MYD88 mutational status.

Topics & Concepts

Cold agglutinin diseaseAutoimmune hemolytic anemiaHemolytic anemiaMedicineBruton's tyrosine kinaseCold AgglutininIbrutinibImmunologyAnemiaAntibodyTyrosine kinaseLeukemiaInternal medicineChronic lymphocytic leukemiaReceptorBlood groups and transfusionErythrocyte Function and PathophysiologyChronic Lymphocytic Leukemia Research
Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome | Litcius